Enviar artigo por via de e-mail Metformin in Type 2 Diabetes: Evidence for its Beneficial Effects on Frailty and Sarcopenia
- Autores: Pyrgioti E.1, Karakousis N.2, Georgakopoulos P.3, Papanas N.2
-
Afiliações:
- Pharmacist, Private Practice, Athens, Greece
- Second Department of Internal Medicine, Diabetes Centre-Diabetic Foot Clinic, Democritus University of Thrace, Alexandroupolis, Greece
- Primary Healthcare, Internal Medicine Department, Amarousion, Attica, Greece
- Edição: Volume 20, Nº 3 (2024)
- Seção: Medicine
- URL: https://rjeid.com/1573-3998/article/view/642980
- DOI: https://doi.org/10.2174/1573399820666230727101141
- ID: 642980
Citar
Texto integral
Resumo
This narrative review aimed to discuss the potential interplay among frailty syndrome, sarcopenia and metformin in type 2 diabetes mellitus (T2DM). There is emerging evidence on the potential protective role of metformin on both frailty and sarcopenia. However, results are not always consistent. Thus, further research is needed to provide a definitive answer on any role of metformin in improving frailty and/or sarcopenia in T2DM.
Palavras-chave
Sobre autores
Elisavet Pyrgioti
Pharmacist, Private Practice, Athens, Greece
Email: info@benthamscience.net
Nikolaos Karakousis
Second Department of Internal Medicine, Diabetes Centre-DiabeticFoot Clinic, Democritus University of Thrace, Alexandroupolis, Greece
Email: info@benthamscience.net
Petros Georgakopoulos
Primary Healthcare, Internal MedicineDepartment, Amarousion, Attica, Greece
Email: info@benthamscience.net
Nikolaos Papanas
Second Department of Internal Medicine, Diabetes Centre-DiabeticFoot Clinic, Democritus University of Thrace, Alexandroupolis, Greece
Autor responsável pela correspondência
Email: info@benthamscience.net
Arquivos suplementares
